Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1

(MedPage Today) -- NEW ORLEANS -- Nivolumab (Opdivo) plus ipilimumab (Yervoy) improved outcomes compared with ipilimumab alone for patients with advanced melanoma who have primary resistance to PD-1 inhibitors, a randomized study found. While...
Source: MedPage Today Dermatology - Category: Dermatology Source Type: news